Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease disrupts hepatic blood flow and reduces enzyme accessibility, impairing drug metabolism. Hepatic clearance depends on blood flow, intrinsic clearance, and their interaction. Tissue damage and altered blood flow reduce the liver's ability to extract and eliminate drugs, increasing drug bioavailability and requiring dose adjustments to prevent toxicity.

Liver disease impairs synthesis of plasma proteins like albumin and globulins, which are essential for drug binding and distribution. Reduced protein production alters how drugs bind and circulate in the bloodstream, affecting drug distribution patterns and therapeutic effectiveness. This disruption necessitates careful monitoring and dose adjustment.

Severe fibrosis and cirrhosis develop shunts that bypass normal hepatic tissue. These shunts reduce the liver's ability to extract drugs from circulation, significantly increasing drug bioavailability. Blood that bypasses the liver avoids metabolism, leading to higher systemic drug concentrations and potential toxicity if doses are not reduced appropriately.

Liver function tests detect tissue damage but do not measure the functionality of specific metabolizing enzymes like cytochrome P450. Since enzyme-dependent drugs rely on these systems for metabolism, reduced enzyme activity cannot be detected by standard liver tests. Therefore, drugs dependent on these enzymes are given in reduced doses to compensate for impaired hepatic function.

Treatment in hepatic failure typically begins with low initial doses while continuously monitoring plasma drug levels. This conservative approach safeguards against drug toxicity while ensuring therapeutic efficacy. Clinical assessments, including physical examination and liver function tests, must corroborate pharmacokinetic calculations to guide safe dose adjustments.

Flow-dependent drugs rely on hepatic blood flow for clearance and are generally avoided or significantly reduced in liver failure due to compromised blood flow. Enzyme-dependent drugs require functional cytochrome P450 systems, which are impaired in hepatic disease. Both drug types require dose reduction, but flow-dependent drugs face additional risk from shunting and reduced hepatic perfusion.

Accurate hepatic clearance calculations must be corroborated with clinical assessments including physical examination and liver function tests. These evaluations help determine the extent of liver damage and dysfunction. Combined with pharmacokinetic calculations, clinical findings guide individualized dose adjustments to optimize drug therapy while minimizing toxicity risk in hepatic failure patients.